References
- Comín E, Solanas P, Cabezas C, et al. Estimating cardiovascular risk in Spain using different algorithms. Rev española Cardiol [Internet]. 2007;60(7):693–702. http://www.ncbi.nlm.nih.gov/pubmed/1766385310.1157/13108274
- Marrugat J, Elosua R, Aldasoro E, et al. Regional variability in population acute myocardial infarction cumulative incidence and mortality rates in Spain 1997 and 1998. Eur J Epidemiol. [Internet] 2004 [cited March 14, 2016];19(9):831–839. http://www.ncbi.nlm.nih.gov/pubmed/15499893
- Gil M, Martí H, Elosúa R, et al. Analysis of trends in myocardial infarction case-fatality, incidence and mortality rates in Girona, Spain, 1990–1999. Rev española Cardiol. [Internet] 2007 [cited March 14, 2016];60(4):349–356. http://www.ncbi.nlm.nih.gov/pubmed/1752154310.1157/13101638
- Marrugat J, Elosua R, Martí H.. Epidemiology of ischaemic heart disease in Spain: estimation of the number of cases and trends from 1997 to 2005. Rev española Cardiol [Internet]. 2002 [cited March 14, 2016];55(4):337–346.http://www.ncbi.nlm.nih.gov/pubmed/1197589910.1016/S0300-8932(02)76611-6
- Masia R, Pena A, Marrugat J, et al. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. REGICOR Investigators. J Epidemiol Community Health [Internet]. 1998 [cited March 14, 2016];52(11):707–715.http://www.ncbi.nlm.nih.gov/pubmed/1039650310.1136/jech.52.11.707
- Grau M, Subirana I, Elosua R, et al. Trends in cardiovascular risk factor prevalence (1995–2000–2005) in northeastern Spain. Eur J Cardiovasc Prev Rehabil [Internet]. 2007 [cited March 14, 2016];14(5):653–659.http://www.ncbi.nlm.nih.gov/pubmed/1792562410.1097/HJR.0b013e3281764429
- Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34(1):121–130.
- Althoff KN, McGinnis KA, Wyatt CM, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 2015;60(4):627–638.10.1093/cid/ciu869
- Womack JA, Chang C-CH, So-Armah KA, et al. HIV infection and cardiovascular disease in women. J Am Heart Assoc [Internet]. 2014;3(5):e001035. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4323817&tool=pmcentrez&rendertype=abstract10.1161/JAHA.114.001035
- Schouten J, Wit FW, Stolte IG, et al. Cross-sectional Comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787–1797.10.1093/cid/ciu701
- Freiberg MS, Chang C-CH, Kuller LH, et al. HIV Infection and the risk of acute myocardial infarction. JAMA Intern Med [Internet]. 2013;173(8):614–622. http://www.ncbi.nlm.nih.gov/pubmed/2345986310.1001/jamainternmed.2013.3728
- Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab [Internet]. 2007;92(7):2506–2512. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2763385&tool=pmcentrez&rendertype=abstract10.1210/jc.2006-2190
- Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet (London, England) [Internet]. 2014 [cited March 15, 2016];384(9939):241–248.http://www.ncbi.nlm.nih.gov/pubmed/2504223410.1016/S0140-6736(14)60604-8
- El-Sadr W, Lundgren J, Neaton J, et al. CD4+count-guided interruption of antiretroviral treatment. N Engl J Med [Internet]. 2006;355(22):2283–2296. http://discovery.ucl.ac.uk/6514/
- Grinspoon SK. Cardiovascular disease in HIV: traditional and nontraditional risk factors. Top Antivir Med. 2014;22(4):676–679.
- Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J [Internet]. 2014;35(21):1373–1381. http://eurheartj.oxfordjournals.org/cgi/doi/10.1093/eurheartj/eht52810.1093/eurheartj/eht528
- Fiscella K, Tancredi D, Franks P. Adding socioeconomic status to Framingham scoring to reduce disparities in coronary risk assessment. Am Heart J [Internet]. 2009 [cited March 15, 2016];157(6):988–994.http://www.ncbi.nlm.nih.gov/pubmed/1946440810.1016/j.ahj.2009.03.019
- Brindle PM, McConnachie A, Upton MN, Hart CL, Davey Smith G, Watt GCM. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract [Internet]. 2005 [cited 2016 Mar 15]; 55(520):838–845.http://www.ncbi.nlm.nih.gov/pubmed/16281999
- Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ [Internet]. 2003 [cited March 15, 2016];327(7426):1267.http://www.ncbi.nlm.nih.gov/pubmed/1464497110.1136/bmj.327.7426.1267
- Parra S, Coll B, Aragonés G, et al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med [Internet]. 2010 [cited March 15, 2016];11(4):225–231.http://www.ncbi.nlm.nih.gov/pubmed/1984579210.1111/hiv.2010.11.issue-4
- Falcone EL, Mangili A, Skinner S, Alam A, Polak JF, Wanke CA. Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV. Antivir Ther [Internet]. 2011 [cited March 15, 2016];16(1):1–8.http://www.ncbi.nlm.nih.gov/pubmed/2131110310.3851/IMP1682
- Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation [Internet]. 1998;97(18):1837–1847. http://circ.ahajournals.org/content/97/18/1837.abstract10.1161/01.CIR.97.18.1837
- Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83(1):356–362.
- Grundy SM, Pasternak R, Greenland P, Smith S Jr., Fuster V. AHA/ACC scientific statement assessment of cardiovascular risk by use of multiple-risk-factor assessment equations association and the American college of cardiology. Circulation. 1999;1097(99):1348–1359.
- Giampaoli S, Palmieri L, Mattiello A, Panico S. Definition of high risk individuals to optimise strategies for primary prevention of cardiovascular diseases. Nutr Metab Cardiovasc Dis [Internet]. 2005;15(1):79–85. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1587185510.1016/j.numecd.2004.12.001
- Wilson PW. Framingham and European risk algorithms: implications for African Americans. Rev Cardiovasc Med. 2004;5(Suppl 3):S34–S41.
- Marrugat J, Solanas P, D’Agostino R, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada [Coronary risk estimation in Spain using a calibrated Framingham function]. Rev Española Cardiol [Internet]. 2003;56(3):253–261. http://www.sciencedirect.com/science/article/pii/S030089320376861410.1016/S0300-8932(03)76861-4
- Friis-Moller N, Ryom L, Smith C, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons; the data-collection on adverse effects of anti-HIV drugs (D:A:D) study. Antivir Ther [Internet]. 2013;18:A23–A24. http://www.intmedpress.com/serveFile.cfm?sUID=bc75b62c-c206-437a-b725-a75baa67f5b2\nhttp://www.embase.com/search/results?subaction=viewrecord&from=export&id=L71281003\nhttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=13596535&id=doi:&atitle=An+updated+pre
- Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation [Internet]. 2014;129(25 suppl 2):S49–S73.http://circ.ahajournals.org/cgi/doi/10.1161/01.cir.0000437741.48606.9810.1161/01.cir.0000437741.48606.98
- Marrugat J, Solanas P, D’Agostino R, et al. Coronary risk estimation in Spain using a calibrated Framingham function. Rev española Cardiol [Internet]. 2003;56(3):253–261. http://www.ncbi.nlm.nih.gov/pubmed/1262295510.1016/S0300-8932(03)76861-4
- Hense H-W, Schulte H, Löwel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany–results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J [Internet]. 2003 [cited March 14, 2016];24(10):937–945.http://www.ncbi.nlm.nih.gov/pubmed/1271402510.1016/S0195-668X(03)00081-2
- Empana JP, Ducimetière P, Arveiler D, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME study. Eur Heart J [Internet]. 2003 [cited March 14, 2016];24(21):1903–1911.http://www.ncbi.nlm.nih.gov/pubmed/1458524810.1016/j.ehj.2003.09.002
- Thomsen TF, McGee D, Davidsen M, Jørgensen T A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup population studies and Framingham heart study. Int J Epidemiol [Internet]. 2002 [cited March 14, 2016];31(4):817–822.http://www.ncbi.nlm.nih.gov/pubmed/1217702810.1093/ije/31.4.817
- Menotti A, Lanti M, Puddu PE, Kromhout D. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart [Internet]. 2000 [cited March 14, 2016];84(3):238–244.http://www.ncbi.nlm.nih.gov/pubmed/1095628110.1136/heart.84.3.238
- Liu J, Hong Y, D’Agostino RB, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study. JAMA [Internet]. 2004 [cited March 14, 2016];291(21):2591–2599.http://www.ncbi.nlm.nih.gov/pubmed/1517315010.1001/jama.291.21.2591
- Ramos R, Solanas P, Cordón F, et al. Comparación de la función de Framingham original y la calibrada del REGICOR en la predicción del riesgo coronario poblacional [Comparison of population coronary heart disease risk estimated by the Framingham original and REGICOR calibrated functions]. Med Clin (Barc). 2003;121(14):521–526.10.1016/S0025-7753(03)74007-X
- Marrugat J. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Heal [Internet]. 2003;57(8):634–638. http://jech.bmj.com/content/57/8/634.full10.1136/jech.57.8.634
- Marrugat J, Subirana I, Comin E, et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA study. J Epidemiol Community Health [Internet]. 2007 [cited March 14, 2016];61(1):40–47.http://www.ncbi.nlm.nih.gov/pubmed/1718301410.1136/jech.2005.038505
- Knobel H, Jericó C, Montero M, et al. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS PatientCare STDS [Internet]. 2007;21(7):452–457. http://www.ncbi.nlm.nih.gov/pubmed/1765102610.1089/apc.2006.0165
- Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction: the data collection on adverse events of anti-HIV drugs (DAD) study group. N Engl J Med. 2003;349:1993–2003.
- Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti‐HIV drugs (D:A:D) study. J Infect Dis. 2010;201(3):318–330.10.1086/649521
- Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42(6):799–805.10.1016/j.jhep.2005.01.022
- Article M. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50(10):1387–1396.
- Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV cohort study. HIV Med. 2013;14(4):195–207.10.1111/hiv.2013.14.issue-4
- Masiá M, Pérez-Cachafeiro S, Leyes M, et al. Cardiovascular risk in human immunodeficiency virus-infected patients in Spain. CoRIS cohort, 2011. Enferm Infecc Microbiol Clin [Internet]. 2012; 30(9):517–527. http://www.ncbi.nlm.nih.gov/pubmed/2255165310.1016/j.eimc.2012.02.014
- García-Lázaro M, Rivero Román A, Camacho Espejo Á, et al. Variability in coronary risk assessment in HIV-infected patients. Med Clin (Barc) [Internet]. 2007; 129(14):521–524. http://www.ncbi.nlm.nih.gov/pubmed/1798352910.1157/13111418
- Baena-Díez JM, García-Lareo M, de la Poza-Abad M, Hernández-Ibáñez R, Muñoz-Rubio A, García-Rey Z. Estimación del riesgo cardiovascular global a partir del riesgo coronario. Estudio de cohortes. Med clÝn (Ed impr) [Internet]. 2006; 127(1):8–10.http://pesquisa.bvsalud.org/portal/resource/es/ibc-046347
- Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task force of the European society of cardiology on cardiovascular mortality and morbidity statistics in Europe. Eur Heart J [Internet]. 1997 [cited March 14, 2016];18(8):1231–1248.http://www.ncbi.nlm.nih.gov/pubmed/945841510.1093/oxfordjournals.eurheartj.a015434
- Levy D, Wilson PW, Anderson KM, Castelli WP. Stratifying the patient at risk from coronary disease: new insights from the Framingham heart study. Am Heart J [Internet]. 1990 [cited March 15, 2016]; 119(3):712–717; discussion 717. http://www.ncbi.nlm.nih.gov/pubmed/213796010.1016/S0002-8703(05)80050-X
- Kannel WB, D’Agostino RB, Sullivan L, Wilson PWF. Concept and usefulness of cardiovascular risk profiles. Am Heart J. 2004:16–26.10.1016/j.ahj.2003.10.022
- Grau M, Subirana I, Elosua R, et al. Why should population attributable fractions be periodically recalculated?. Prev Med (Baltim) [Internet]. 2010 [cited March 15, 2016];51(1):78–84.http://www.ncbi.nlm.nih.gov/pubmed/2036261010.1016/j.ypmed.2010.03.012
- Medrano MJ, Pastor-Barriuso R, Boix R, et al. Coronary disease risk attributable to cardiovascular risk factors in the Spanish population. Rev española Cardiol [Internet]. 2007 [cited March 15, 2016];60(12):1250–1256. http://www.ncbi.nlm.nih.gov/pubmed/1808209010.1157/13113930
- Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med [Internet]. 2007;356(17):1723–1735. http://www.ncbi.nlm.nih.gov/pubmed/17460226\nhttp://www.nejm.org/doi/abs/10.1056/NEJMoa062744
- Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A: D study: a multi-cohort collaboration. Lancet [Internet]. 2008;371(9622):1417–1426. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2688660&tool=pmcentrez&rendertype=abstract